Alison W. Loren, Marco Mielcarek, Javier Bolaños‐Meade, Jonathan E. Brammer, Meredith Cowden, Antonio Di Stasi, Areej El‐Jawahri, Hany Elmariah, Krishna Gundabolu, Jonathan A. Gutman, Vincent T. Ho, Rasmus T. Hoeg, Mitchell E. Horwitz, Omer Jamy, Adetola A. Kassim, Mohamed Kharfan Dabaja, Lauren Lee, Aaron C. Logan, Christina Luszcak, John Magenau, Thomas Martin, Varun Mittal, Jonathan Moreira, Lori Muffly, Ryotaro Nakamura, Mariam Nawas, Yago Nieto, Cameron Ninos, Caspian Oliai, Genovefa A. Papanicolaou, Joseph A. Pidala, Brion Randolph, Mark A. Schroeder, Jeffrey Tessier, Jeffrey Topal, Dimitrios Tzachanis, Asya Varshavsky‐Yanovsky, Frankie Jones, Katie Stehman
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.